Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immune response |
| gptkbp:administeredBy |
hepatitis B vaccine
|
| gptkbp:approvedBy |
1970s
|
| gptkbp:ATCCode |
gptkb:J06BB04
|
| gptkbp:brand |
gptkb:Bayhep_B
gptkb:HepaGam_B gptkb:HyperHEP_B gptkb:Nabi-HB |
| gptkbp:category |
antiviral drug
biological product |
| gptkbp:contraindication |
severe allergic reaction to human immunoglobulin
|
| gptkbp:eliminationHalfLife |
about 3 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hepatitis B Immune Globulin
|
| gptkbp:indication |
protection of newborns of hepatitis B positive mothers
post-exposure prophylaxis for hepatitis B |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
provides passive immunity to hepatitis B virus
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intramuscular injection
intravenous injection |
| gptkbp:sideEffect |
fever
nausea injection site reaction allergic reaction |
| gptkbp:source |
human plasma
|
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
prevention of hepatitis B
|
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:Cangene_Corporation
|
| gptkbp:bfsLayer |
6
|